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Abstract
Background: Adoptive immune and vaccine therapies have been used to prevent cytomegalovirus
(CMV) disease in recipients of hematopoietic progenitor cell transplants, but the nature of T cell
responses to CMV have not been completely characterized.
Methods: Peptide pools and individual peptides derived from the immune-dominant CMV proteins
pp65 and IE-1 and antigen-specific, cytokine flow cytometry were used to characterize the
prevalence and frequency of CD4+ and CD8+ memory T cells in 20 healthy CMV-seropositive
subjects.
Results: CD8+ T cell responses to pp65 were detected in 35% of subjects and to IE-1 in 40% of
subjects. CD4+ T cell responses to pp65 were detected in 50% of subjects, but none were detected
to IE-1. Several new IE-1 HLA class I epitopes were identified, including 4 restricted to HLA-C
antigens. One region of IE-1 spanning amino acids 300 to 327 was rich in class I epitopes. The HLA
class I restrictions of IE-1 peptides were more promiscuous than those of pp65 peptides.
Conclusion: Since naturally occurring CD4+ and CD8+ T cell responses to pp65 were detectable
in many subjects, but only CD8+ T cell responses to IE-1 were detected, pp65 may be better than
IE-1 for use in vaccine and adoptive immune therapies.
Background
Cytomegalovirus (CMV) is a persistent virus in normal
hosts in which primary infection is typically controlled
through a combination of adaptive and innate immune
responses. Viral latency follows primary infection and
continues for life, usually without major symptoms.
Although 60% to 80% of adults that test seropositive for
CMV antibodies show no symptoms of infection, in
immunocompromised hosts, such as patients undergoing
hematopoietic stem cell transplantation (HSCT) or recip-
ients of organ transplants, CMV can cause severe dis-
ease[1]. In the past 10 years, the incidence of CMV disease
in allogeneic HSCT recipients during the first 100 days
after transplantation fell from 40% to 5% as a result of
improved diagnosis and prophylactic or preemptive treat-
ment with antiviral drugs. However, the effect of the
improved therapy has delayed disease onset to 6 to 12
months after transplantation, and the risk of severe CMV
disease remains in 10% of allogeneic HSCT recipients[2].
In order to control rather than delay the incidence of CMV
disease after HSCT, the host's anti-CMV immunity must
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be restored. Because CMV immunotherapy is growing in
importance, the study of the immune response to CMV is
clinically relevant. T cell immunity is believed to be the
most important component in immune response to CMV
disease. This is supported by the fact that Natural Killer
cells recover early after HSCT, before the peak incidence of
CMV disease, and by the failure of infusion of immu-
noglobulin (Ig) preparations containing antiviral anti-
bodies to control the disease [3,4]. In contrast, clinical
trials involving adoptive transfer of CMV-specific T cells
were successful in restoring immunity against the virus
[5,6]. An alternative to adoptive immunotherapy is vacci-
nation of HSCT donors against CMV with the aim of pro-
viding specific immunity to the recipient for protection
against primary infection or reactivation[7].
Two CMV proteins, phosphoprotein 65 (pp65) and
immediate early protein-1 (IE-1), have been found to be
major targets of the cellular immune response [8-12].
Immunodominant epitopes in these proteins have been
defined for some human leukocyte antigen (HLA) alleles,
but further definition for specific major-histocompatibil-
ity complex (MHC) classes and HLA allelic restrictions
could be useful for adoptive immune therapy, vaccine
therapy, and in screening for reactivation after immuno-
suppression[13,14].
The purpose of this study was to characterize the natural
repertoire of immunodominant pp65 and IE-1 epitopes
in 20 CMV-seropositive, healthy subjects. Donor CD4+
and CD8+ T cell responses to CMV pp65 and IE-1 15-mer
peptide libraries were defined and followed downstream
to the individual 15-mer and nanomer peptides, respec-
tively. This process identified epitopes without biases
introduced by focusing on specific immunodominant
regions for individual HLA types.
Methods
Study design
In this study, 20 CMV-seropositive and 5 CMV-seronega-
tive healthy donors were evaluated. To determine the
CD8+ and CD4+ T cell responses to CMV in the 25
donors, peripheral blood mononuclear cells (PBMCs)
were stimulated in vitro with a cocktail of 15-mer peptides
overlapping by 11 residues and covering the pp65 and IE-
1 proteins. Antigen-specific cytokine flow cytometry was
used to detect specific T cell responses[15,16]. To define
immunodominant epitopes, PBMCs were also stimulated
with subpools of pp65 and IE-1, each subpool containing
10 overlapping 15-mer peptides. PBMCs reactive to a sub-
pool were then tested further against the individual pep-
tides contained within the subpool to determine the
reactive 15-mer(s). In order to further characterize
epitopes presented to CD8+ T cells by HLA class I anti-
gens, PBMCs from donors with reactive CD8+ cells were
tested again with nanomer peptides spanning the reactive
15-mer peptide and overlapping at 8 amino acids (Figures
1 and 2). These studies were approved by a National Insti-
tutes of Health Institutional Review Board on the use of
Human Subjects in Research.
Collection of PBMCs
PBMC concentrates from 20 CMV-seropositive and 5
CMV-seronegative healthy donors were collected by
apheresis, (Fenwal CS-3000 Plus, Baxter Healthcare Corp,
Deerfield, IL) and peripheral blood mononuclear cells
were isolated by ficoll-hypaque density gradient separa-
tion and frozen in aliquots of 1 × 108 cells. Donors were
typed for HLA class I and class II alleles using sequence-
specific primers and, in some cases, direct sequencing
(HLA Laboratory, DTM, CC, NIH, Bethesda, MD). The
presence of IgG and IgM CMV antibodies in each subject
was analyzed by passive agglutination (BD, Microbiologi-
cal Systems, Cockeysville, MD).
Peptide libraries and pools
Libraries for CMV proteins pp65 and IE-1 were made up
of peptides 15 amino acids long that overlapped by 11
residues and covering the complete pp65 (CMV Towne)
[17] and IE-1 (CMV AD169) proteins[18]. The pp65
library was made up of 138 peptides and the IE-1 library
of 120 peptides, and both were commercially synthesized
(Princeton Biomolecules, Langhorne, PA). Peptides were
diluted in dimethyl sulfoxide and pooled into cocktails
containing the complete pp65 and IE-1 protein sequences
and into subpools containing 10 consecutive peptides
each. Pp65 was divided into 13 subpools of 10 peptides
and 1 subpool of 8 peptides, and IE-1 was divided into 12
subpools of 10 peptides (Figures 1 and 2).
PBMC stimulation and flow cytometric assessment
T cell activation was assessed by measuring intracellular
interferon gamma (IFN-γ) production by flow cytometry
after PBMC stimulation. PBMCs were plated at 1–5 × 106
per mL in 24-well plates with 1 mL of complete medium
(CM) supplemented with 10% heat-inactivated human
AB serum, 10 μM HEPES buffer, 100 U/mL penicillin-
streptomycin, 0.03% L-glutamine, and 10 mg/mL cipro-
floxacin. Following overnight resting at 37°C, PBMCs
were stimulated with 1 μg/mL of pp65 and IE-1 libraries,
sub-pools, or individual peptides and 0.5 mg/mL of sta-
phylococcal enterotoxin B (SEB) (Sigma, St Louis, MO) as
a positive control.
After 1 h of incubation at 37°C, 2 μg/ml of Brefeldin A
(BFA) (Sigma) was added, and the cells were incubated for
an additional 5 h before harvesting, fixed in FACS Lysing
Solution (BD Biosciences, San Jose, CA) at room temper-
ature and rested overnight at 4°C. The following day
PBMCs were washed, permeabilized in Perm2 SolutionJournal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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and stained with monoclonal antibodies against CD3-
PerCP, CD8-PE, CD4-APC and IFNγ-FITC (all from BD
Biosciences) and incubated at 4°C for 30 minutes. Mouse
Ig isotype controls were also used (BD Biosciences). The 2-
laser FACSCalibur flow cytometer and CellQuest Pro soft-
ware (BD Biosciences) were used for analysis by acquiring
200,000 events, and determining the viable lymphocyte
population by light scatter. Gates were designed for CD3+
expression and for characterization of CD8+ and CD4+
subpopulations. The proportion of reactive CD8+ and
CD4+ cells was expressed as a percent of the total number
of CD8+ and CD4+ cells analyzed, respectively.
Reactive populations met 2 criteria: (1) well-defined cell
population reactive with both IFN-γ and CD8+ or CD4+,
and (2) the percentage of IFN-γ producing cells was
greater than 3 standard deviations of the percentage of
unstimulated IFN-γ producing cells. Scattered reactive
cells were not sufficient to be considered a positive popu-
lation.
Determination of HLA restriction
Epitope HLA restrictions were determined by testing the
ability of peptide-pulsed Epstein-Barr Virus (EBV) trans-
formed lymphoblastoid B cell lines (EBV-LCL) to stimu-
late T cells that were sensitized in vitro with the same
peptide. In vitro sensitization involved an 8 to10 day cell
culture in the presence of the determined CMV nanomers
or 15-mers. PBMCs were plated at a concentration of 1 ×
107 PBMC per mL in a 24 well-plate with 2 mL CM, and
Identification of CMV pp65 epitopes using 15-mer and nanomer peptides Figure 1
Identification of CMV pp65 epitopes using 15-mer and nanomer peptides. PBMCs were stimulated with a library of 
138 15-mer peptides overlapping by 11 residues and covering the entire pp65 protein. IFN-γ flow cytometry was used to 
detect T cell responses. To identify specific epitopes, PBMCs were stimulated with subpools containing 10 overlapping 15-mer 
peptides. PBMCs from donors reactive with CD4+ T cells were tested further with individual 15-mers. The results of analysis 
of CD4+ T cell responses in donor 14 to pp65 peptides are shown.
1. MESRGRRCPEMASVL
2. GRRCPEMASVLGPIS
3. PEMASVLGPISGHVL
4. SVLGPISGHVLKAVF
5. PISGHVLKAVFSRGD
6. HVLKAVFSRGDTPVL
7. AVFSRGDTPVLPHET
------
--------
---------
133. GVWQPAAQPKRRRHR
134. PAAQPKRRRHRQDAL
135. PKRRRHRQDALPGPC
136. RHRQDALPGPCIAST
137. DALPGPCIASTPKKH
138. LPGPCIASTPKKHRG
Peptide maxi pool:
138 peptides
pp65 protein
MESRGRRCPEMASVLGPISGHVLKAVFSRGDTPVLPHETRLLQTGIHVRVSQPSLILVSQYTPDSTPCHRGDNQLQVQHTYFTGSEVENVSVNVHNPTG
RSICPSQEPMSIYVYALPLKMLNIPSINVHHYPSAAERKHRHLPVADAVIHASGKQMWQARLTVSGLAWTRQQNQWKEPDVYYTSAFVFPTKDVALRHV
VCAHELVCSMENTRATKMQVIGDQYVKVYLESFCEDVPSGKLFMHVTLGSDVEEDLTMTRNPQPFMRPHERNGFTVLCPKNMIIKPGKISHIMLDVAFT
SHEHFGLLCPKSIPGLSISGNLLMNGQQIFLEVQAIRETVELRQYDPVAALFFFDIDLLLQRGPQYSEHPTFTSQYRIQGKLEYRHTWDRHDEGAAQGD
DDVWTSGSDSDEELVTTERKTPRVTGGGAMAGASTSAGRKRKSASSATACTAGVMTRGRLKAESTVAPEEDTDEDSDNEIHNPAVFTWPPWQAGILARN
LVPMVATVQGQNLKYQEFFWDANDIYRIFAELEGVWQPAAQPKRRRHRQDALPGPCIASTPKKHRG
14 mini pools: 
10 peptides each
pp65 pool 1
1. MESRGRRCPEMASVL
2. GRRCPEMASVLGPIS
3. PEMASVLGPISGHVL
4. SVLGPISGHVLKAVF
5. PISGHVLKAVFSRGD
6. HVLKAVFSRGDTPVL
7. AVFSRGDTPVLPHET
8. RGDTPVLPHETRLLQ
9. PVLPHETRLLQTGIH 
10.HETRLLQTGIHVRVS
SS SS SS SS   SRRO SRRO SRRO SRRO   
pp65 pool 2
pp65 pool –
pp65 pool 14
131. YRIFAELEGVWQPAA
132. AELEGVWQPAAQPKR
133. GVWQPAAQPKRRRHR
134. PAAQPKRRRHRQDAL
135. PKRRRHRQDALPGPC
136. RHRQDALPGPCIAST
137. DALPGPCIASTPKKH
138. LPGPCIASTPKKHRG
Single peptides:
1 through 138
1. MESRGRRCPEMASVL
2. GRRCPEMASVLGPIS     
-------------
138. LPGPCIASTPKKHRG
IFN-γ
C
D
4
100 101 102 103 104
IFNG-FITC
Data.008
pp65 library
1.34%
100 101 102 103 104
IFNG-FITC
Data.019
Sub-pool 10
0.96%
100 101 102 103 104
IFNG-FITC
Data.024
15-mer pp65365-379
0.56%Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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directly stimulated with 1 μg/mL of pre-determined pep-
tide. Recombinant human interleukin-2 (50 U/mL, Chi-
ron, Emeryville, CA) was added to the cells at 24 hours
and every other day.
Partially HLA matched EBV-LCL panels were developed
for each donor, to match HLA class I or class II antigens.
EBV-LCLs in CM were pulsed with 1 μg/mL of peptide and
incubated at 37°C for 1 h, mixing vigorously at 30 m
intervals. Washed EBV-LCLs were resuspended in CM at 1
× 106 cells per mL, and 1 mL was added to the sensitized
cells which were plated according to the methods
described above. The plates were centrifuged for 2 min-
utes at 500 rpm and incubated for 1 h at 37°C before add-
ing 2 μg/mL of BFA and incubating for an additional 5 h.
Samples were treated and analyzed as described above.
Results
Peripheral blood was obtained from 25 healthy subjects;
20 CMV-seropositive and 5 CMV-seronegative, similar in
age, gender, and race (Table 1). The HLA types of the sub-
jects were representative of the general population (Table
2). PBMCs from all 25 subjects were tested against the
complete pp65 peptide library and subpools (Figure 1)
and the complete IE-1 peptide library and subpools (Fig-
ure 2).
T cell responses to the complete pp65 and IE-1 peptide 
libraries
Neither the complete pp65 or IE-1 libraries stimulated
CD8+ or CD4+ T cells from the 5 CMV-seronegative sub-
jects (Table 3). The proportion of CD8+ cells producing
intracellular IFN-γ in response to the pp65 library ranged
from 0.02% to 0.09%, and in response to the IE-1 library
Identification of CMV IE-1 epitopes using 15-mer and nanomer peptides Figure 2
Identification of CMV IE-1 epitopes using 15-mer and nanomer peptides. PBMCs were stimulated with a library of 
120 15-mer peptides overlapping by 11 residues and covering the entire IE-1 protein. IFN-γ flow cytometry was used to detect 
T cell responses. To identify specific epitopes, PBMCs were stimulated with peptide subpools containing 10 overlapping 15-
mer peptides. PBMCs from donors with reactive CD8+ T cells were tested further with individual 15-mers and nanomers. The 
results of analysis of CD8+ T cell responses in donor 6 to IE-1 peptides are shown.
IE-1 protein
MESSAKRKMDPDNPDEGPSSKVPRPETPVTKATTFLQTMLRKEVNSQLSLGDPLFPELAEESLKTFEQVTEDCNENPEKDVLAELVKQIKVRVDMVRHR
IKEHMLKKYTQTEEKFTGAFNMMGGCLQNALDILDKVHEPFEEMKCIGLTMQSMYENYIVPEDKREMWMACIKELHDVSKGAANKLGGALQAKARAKKD
ELRRKMMYMCYRNIEFFTKNSAFPKTTNGCSQAMAALQNLPQCSPDEIMAYAQKIFKILDEERDKVLTHIDHIFMDILTTCVETMCNEYKVTSDACMMT
MYGGISLLSEFCRVLCCYVLEETSVMLAKRPLITKPEVISVMKRRIEEICMKVFAQYILGADPLRVCSPSVDDLRAIAEESDEEEAIVAYTLATAGVSS
SDSLVSPPESPVPATIPLSSVIVAENSDQEESEQSDEEEEEGAQEEREDTVSVKSEPVSEIEEVAPEEEEDGAEEPTASGGKSTHPMVTRSKADQ
1. MESSAKRKMDPDNPD 
2. AKRKMDPDNPDEGPS
3. PDPDNPDEGPSSKVP
4. NPDEGPSSKVPRPET
5. GPSSKVPRPETPVTK
6. KVPRPETPVTKATTF
7. PETPVTKATTFLQTM
------
--------
---------
115. IEEVAPEEEEDGAEE
116. APEEEEDGAEEPTAS
117. EEDGAEEPTASGGKS
118. AEEPTASGGKSTHPM
119. TASGGKSTHPMVTRS
120. GKSTHPMVTRSKADQ
Peptide maxi pool:
120 peptides
IE-1 pool 1
1. MESRGRRCPEMASVL
2. GRRCPEMASVLGPIS
3. PEMASVLGPISGHVL
4. SVLGPISGHVLKAVF
5. PISGHVLKAVFSRGD
6. HVLKAVFSRGDTPVL
7. AVFSRGDTPVLPHET
8. RGDTPVLPHETRLLQ
9. PVLPHETRLLQTGIH 
10.HETRLLQTGIHVRVS
IE-1 pool 2
IE-1 pool –
IE-1 pool 12
111. EEREDTVSVKSEPVS
112. DTVSVKSEPVSEIEE
113. VKSEPVSEIEEVAPE 
114. PVSEIEEVAPEEEED 
115. IEEVAPEEEEDGAEE 
116. APEEEEDGAEEPTAS 
117. EEDGAEEPTASGGKS 
118. AEEPTASGGKSTHPM 
119. TASGGKSTHPMVTRS
120. GKSTHPMVTRSKADQ
12 mini pools: 
10 peptides each
Single peptides:
1 through 120
1. MESSAKRKMDPDNPD 
2. AKRKMDPDNPDEGPS
-------------
120. GKSTHPMVTRSKADQ
IFN-γ
C
D
8
100 101 102 103 104
IFNG-FITC
9-mer IE-1300-308
2.55%
100 101 102 103 104
IFNG-FITC
IE-1 library
0.87%
100 101 102 103 104
IFNG-FITC
Sub-pool 8
1.05%
100 101 102 103 104
IFNG-FITC
15-mer IE-1297-311
0.70%Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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ranged from 0.00% to 0.05%. The proportion of CD4+
cells producing IFN-γ in response to the pp65 library
ranged from 0.00% to 0.04% and in response to the IE-1
library ranged from 0.01% to 0.04%. PBMCs were also
tested against the subpools, none of which induced signif-
icant IFN-γ.
Testing PBMCs from each of the 20 CMV-seropositive sub-
jects revealed that the pp65 and IE-1 libraries stimulated
CD8+ T cells in 7 (35%) and 8 (40%) subjects, respec-
tively. IFN-γ producing cells ranged from 0.12% to 0.70%
for pp65 and 0.32% to 2.06% for IE-1 (Table 4). CD4+
cells were stimulated by the pp65 library in 10 (50%) sub-
jects with the percent of IFN-γ producing cells ranging
from 0.11% to 3.33%, but were not stimulated in any
donors by the IE-1 library (Table 4).
CD8+ T cell responses to pp65 peptides
Testing of PBMCs from all 20 CMV-seropositive donors
against the pp65 subpools revealed that all 7 subjects with
CD8+ cells that were reactive to the pp65 library reacted
to at least 1 pp65 subpool. We identified 5 reactive pp65
subpools, with subpool 11 stimulating CD8+ cells from 3
subjects (Table 5).
All of the 15-mer peptides in each of the reactive sub-
pools, 3, 5, 6, 11, and 13 were tested against PBMCs from
the corresponding subjects, and we identified 6 reactive
pp65 15-mer peptides (Figure 3). Four of the 6 reactive
peptides each elicited a CD8+ T cell response in 1 subject,
donors 5, 10, 13, and 19. The other 2 reactive peptides
were overlapping 15-mers that elicited responses in
donors 3, 7 and 14.
Since HLA class I antigens usually present peptides of 9 or
10 amino acids long to CD8+ T cells, nanomers were syn-
thesized that spanned each reactive 15-mer and that over-
lapped by 8 amino acids. We identified 5 epitopes by
testing each nanomer against PBMCs from donor(s) reac-
tive with the corresponding 15-mer (Figure 3). Three of
the 15-mers each yielded 1 epitope, pp65123–131, pp65188–
196, and pp65495–503, in donors 19, 5, and 13, respectively
(Figure 3). The nanomers spanning 2 overlapping 15-
mers, pp65413–427 and pp65417–431, yielded 2 epitopes,
pp65417–425 and pp65418–426 (Figure 3). However, nano-
mers covering pp65221–235, did not stimulate any cells.
Both pp65417–425 and pp65418–426 stimulated CD8+ cells
from donors 3, 7, and 14, all of whom expressed HLA-
B*07 (Table 6). The restriction to HLA-B*07 was con-
firmed by testing donor 14 PBMCs sensitized in vitro for
10 days with pp65418–426 against EBV-LCLs pulsed with
pp65418–426. CD8+ IFN-γ production was detected when
the in vitro sensitized PBMCs were tested against peptide-
loaded EBV-LCLs expressing HLA-B*07, but not those
expressing the other donor 14 HLA class I antigens. Simi-
lar epitopes, pp65415–429 and pp65417–426 have been previ-
ously found to be presented by HLA-B*07[8,19].
The peptide pp65123–131 has been described as restricted to
HLA-B*35, and we found this peptide to stimulate CD8+
cells from donor 19, who also expressed HLA-B*35 (Table
6)[20]. This restriction was confirmed by testing donor 19
PBMCs that were ex vivo sensitized with pp65123–131
against EBV-LCLs loaded with pp65123–131. CD8+ T cells
produced IFN-γ when tested against pp65123–131-loaded
EBV-LCLs expressing HLA-B*35 but not those expressing
other donor 19 HLA class I antigens.
The epitope pp65495–503  stimulated CD8+ cells from
donor 13, who expressed HLA-A*02 (Table 6). Since this
epitope has been described by several groups as being
restricted to HLA-A*02, we did not test this peptide fur-
ther[8,13,21].
Table 1: Age, Gender, and Race of Subjects Studied
CMV-Seropositive n = 20 CMV-Seronegative n = 5 All n = 25
Age, years
Median 45.1 42.8 44.6
Range 17–64 35–49 17–64
Gender
Male, % 80 80 80
Race
White, % 55 60 56
Black, % 40 20 36
Hispanic, % 5 0 4
Unknown, % 0 20 4Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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The epitope pp65188–196  stimulated CD8+ cells from
donor 5, who expressed HLA-A*05; -B*11, 68, and -C*05,
06 (Table 6). Unfortunately, no PBMCs were available to
test. However, pp65186–196 has been described as being
restricted to HLA-B*35 and HLA-A*6801/02[20], so it is
possible that in this donor, pp65188–196 is restricted to
HLA-A*68[8,21].
CD8+ T cell responses to IE-1 peptides
The 12 IE-1 subpools were tested against all 20 subjects
and 4 subpools induced IFN-γ in 8 subjects (Table 7). At
least 1 IE-1 subpool induced IFN-γ production in CD8+ T
cells from all 8 subjects with cells reactive with the IE-1
library. One subpool stimulated CD8+ cells in 5 subjects,
another stimulated CD8+ cells in 3 subjects, and 2 other
subpools stimulated CD8+ cells from 1 subject (Table 7).
Testing the 15-mers in IE-1 subpool 5 against PBMCs
from donor 15 identified IE-1197–211 as the reactive 15-mer
and IE-1198–206 as the reactive nanomer (Figure 4). Testing
the 15-mers in subpool 10 against cells from donor 15
revealed that IE-1373–387 as the reactive 15-mer and IE-
1378–386 as the reactive nanomer (Figure 4), and testing of
subpool 3 peptides against PBMCs from donors 5, 10, and
11 identified IE-181–95and IE-187–95 as the reactive 15-mer
and nanomer (Figure 4).
Testing subpool 8 peptides revealed that one 15-mer and
1 nanomer were reactive with cells from donor 6, IE-1297–
311 (Figure 5a) and IE-1300–308 (Figure 5b), respectively.
Testing of subpool 8 peptides against cells from donors 2,
5, and 7 identified 3 reactive 15-mers: IE-1305–319, IE-1309–
323, and IE-1313–327(Figure 5a), and 4 reactive nanomers:
Table 2: HLA Genotype of the 20 CMV-Seropositive Subjects Studied
HLA Type
Donor Race Class I Class ll
A* B* C* DRB1* DRB- DQB1*
1 Black 01, 0301 15, 81 05, 18 0901, 11 3*00, 4*01 02, 06
2 Caucasian 24, 32 07, 40 02, 07 0401, 1302 3*0301, 4*0103 03, 0609
3 Caucasian 01, 31 07, 27 0202, 0702 0801, 1501 5*01, 5*01 04, 06
4 Black 30, 3601 53, 53 04, 04 03, 1001 3*01, 3*01 04, 05
5 Hispanic 11, 68 44, 45 05, 06 0404, 1101 3*02, 4*0103 03, 03
6 Black 26, 30 35, 57 04, 18 11, 16 3*02, 5*02 0301, 05
7 Caucasian 01, 0201 07, 35 04, 07 0401, 0701 4*01, 4*01 0303, 03
8 Black 0202, 30 4901, 53 04, 07 13031, 1503 3*02, 3*02 02, 06
9 Caucasian 23, 32 35, 41 04, 17 11, 11 3*02, 3*02 03, 06
10 Black 0301, 68 53, 58 04, 06 0701, 1302 3*0301, 4*0401 0202, 0604
11 Black 26, 74 15, 5802 0602, 1601 0102, 1101 3*0202, 3*0202 0301, 0501
12 Black 0202, 68 5301, 5301 04, 04 03021, 1503 3*01, 5*01 04, 06
13 Caucasian 0201, 0201 15, 18 03, 07 13, 1501 3*02, 5*01 06, 06
14 Caucasian 010101, 2601 070201, 3801 070201, 120301 0402, 1101 3*02, 4*0103 0301, 0302
15 Caucasian 0201, 30 18, 44 0501, 0501 04, 13 3*02, 4*01 03, 06
16 Caucasian 0201, 11 07, 40 03, 07 0301, 1501 3*01, 5*01 02, 06
17 Caucasian 0201, 0201 15, 18 03, 07 13, 1501 3*02, 5*01 06, 06
18 Black 2301, 24 07, 18 0202, 0702 07, 15 4*01, 5*01 02, 06
19 Caucasian 03, 29 35, 44 04, 1601 01, 0701 4*01, 4*01 0202, 0501
20 Caucasian 03, 11 07, 5601 01, 07 0101, 0701 4*01, 4*01 02, 0501
Table 3: Proportion of Peripheral Blood CD8+ and CD4+ T Cells from 5 Healthy CMV-Seronegative Subjects Producing Intracellular 
IFN-γ Following Stimulation With a Library of 138 CMV pp65 or 120 CMV IE-1 15-mer Peptides
Proportion of T Cells Producing Intracellular IFN-γ(%) in Each Donor
L i b r a r y C e l l  T y p e 12345
pp65 CD8+ 0.02 0.03 0.03 0.08 0.09
IE-1 CD8+ 0.04 0.02 0.01 0.00 0.05
pp65 CD4+ 0.00 0.03 0.02 0.02 0.03
IE-1 CD4+ 0.01 0.01 0.02 0.01 0.04Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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IE-1305–313, IE-1308–316, IE-1312–320, and IE-1319–327 (Figure
5c).
Among the 8 IE-1 epitopes identified, IE-187–95, IE-1300–
308, IE-1305–313, IE-1312–320, and IE-1319–327 have not been
previously described. The peptide IE-187–95  stimulated
CD8+ cells from 3 donors, all of whom expressed HLA-
C*06 (Table 8) and this restriction was confirmed by test-
ing donor 11 in vitro sensitized PBMCs against IE-187–95-
loaded EBV-LCLs.
The peptide IE-1305–313 stimulated cells from donor 7,
who expressed HLA-A*01, 0201; -B*07, 35; and -C*04,
07. Testing donor 7 PBMCs that were in vitro sensitized
with IE-1305–313 against IE-1305–313-loaded EBV-LCLs con-
firmed that this epitope was restricted to HLA-C*07
(Table 8).
The peptide IE-1308–316 stimulated cells from donors 2 and
7, both expressing HLA-B*07 and -C*07. Testing donor 7
PBMCs that were in vitro sensitized with IE-1308–316
against IE-1308–316-loaded EBV-LCLs confirmed the restric-
tion to HLA-C*07 (Table 8). However, an overlapping
peptide, IE-1309–317, has been reported to be restricted to
HLA-B*0702[9].
The peptide IE-1312–320 stimulated cells from donor 7 and
testing of PBMCs that were in vitro sensitized with IE-
1312–320 against peptide-loaded EBV-LCLs revealed restric-
tion to HLA-C*07 (Table 8).
The peptide IE-1319–327 stimulated cells from donor 5,
who expressed A*11,68; -B*44,45; and -C*05,06. Testing
PBMCs that were in vitro sensitized with IE-1319–327
against peptide-loaded EBV-LCLs revealed that IE-1319–327
was restricted to HLA-A*68.
The peptide IE-1300–308 stimulated CD8+ cells from donor
6 however, no PBMCs were available for testing.
Table 5: Proportion of Peripheral Blood CD8+ T Cells From 20 Healthy CMV-Seropositive Subjects Producing Intracellular IFN-γ 
Following Stimulation With a Library of 138 CMV pp65 15-mer Peptides and Each of 14 subpools of 10 Peptides*
CD8+ T Cells Producing Intracellular IFN-γ in Each Donor (%)
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0
Library 0.02 0.06 0.37 0.10 0.27 0.13 0.70 0.13 0.13 0.27 0.11 0.18 0.12 0.27 0.07 0.08 0.06 0.05 0.18 0.03
Subpool
1 0.01 0.04 0.07 0.03 0.01 0.02 0.02 0.02 0.01 0.01 0.12 0.09 0.14 0.03 0.01 0.08 0.01 0.00 0.02 0.03
2 0.01 0.05 0.02 0.03 0.17 0.05 0.11 0.05 0.06 0.03 0.03 0.08 0.01 0.03 0.06 0.08 0.03 0.03 0.03 0.02
3 0.02 0.02 0.07 0.13 0.04 0.06 0.15 0.01 0.03 0.02 0.03 0.16 0.03 0.04 0.03 0.03 0.05 0.01 0.27 0.02
4 0.02 0.04 0.03 0.01 0.10 0.08 0.18 0.08 0.06 0.09 0.01 0.08 0.02 0.05 0.07 0.02 0.00 0.05 0.05 0.02
5 0.04 0.01 0.02 0.03 0.13 0.04 0.08 0.07 0.11 0.00 0.04 0.06 0.08 0.02 0.03 0.08 0.01 0.01 0.03 0.02
6 0.00 0.01 0.00 0.14 0.08 0.03 0.04 0.05 0.08 0.21 0.05 0.06 0.03 0.03 0.11 0.08 0.03 0.04 0.01 0.02
7 0.03 0.06 0.03 0.03 0.04 0.01 0.11 0.07 0.07 0.08 0.03 0.07 0.08 0.15 0.03 0.03 0.02 0.10 0.03 0.02
8 0.02 0.00 0.03 0.01 0.03 0.10 0.01 0.10 0.03 0.01 0.03 0.08 0.03 0.02 0.02 0.10 0.02 0.04 0.03 0.05
9 0.05 0.03 0.00 0.06 0.02 0.03 0.03 0.02 0.03 0.02 0.05 0.12 0.02 0.04 0.02 0.05 0.03 0.04 0.03 0.13
10 0.06 0.02 0.00 0.05 0.02 0.10 0.14 0.06 0.03 0.04 0.06 0.05 0.02 0.08 0.03 0.06 0.03 0.03 0.04 0.02
11 0.02 0.02 0.17 0.01 0.02 0.06 0.36 0.04 0.06 0.04 0.05 0.12 0.01 0.13 0.01 0.05 0.01 0.01 0.00 0.02
12 0.12 0.08 0.03 0.00 0.07 0.02 0.06 0.05 0.09 0.01 0.03 0.04 0.01 0.03 0.00 0.08 0.02 0.03 0.02 0.05
13 0.05 0.05 0.02 0.00 0.01 0.02 0.06 0.06 0.07 0.04 0.08 0.07 0.12 0.03 0.04 0.03 0.09 0.03 0.01 0.02
14 0.03 0.01 0.02 0.01 0.10 0.04 0.06 0.07 0.08 0.08 0.06 0.07 0.02 0.01 0.03 0.02 0.02 0.05 0.04 0.00
* Subpool 14 contained 8 peptides
Positive CD8+ T cell assays are indicated in bold and italics.
Table 4: Proportion of Peripheral Blood CD8+ and CD4+ T Cells From 20 Healthy CMV-Seropositive Subjects Producing Intracellular 
IFN-γ Following Stimulation With a Library of 138 CMV pp65 or 120 CMV IE-1 15-mer Peptides
Proportion of T Cells Producing Intracellular IFN-γ(%) in Each Donor
L i b r a r y C e l l123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0
pp65 CD8+ 0.02 0.06 0.37 0.10 0.27 0.13 0.70 0.13 0.13 0.27 0.11 0.18 0.12 0.27 0.07 0.08 0.06 0.05 0.18 0.03
IE-1 CD8+ 0.05 0.46 2.06 0.04 1.65 0.87 1.37 0.13 0.15 0.33 0.32 0.06 0.02 0.12 1.41 0.05 0.05 0.02 0.03 0.08
pp65 CD4+ 0.16 0.06 0.00 0.06 0.11 0.76 0.11 0.65 0.08 0.21 3.33 0.18 0.20 1.34 0.23 0.02 0.15 0.03 0.04 0.01
I E - 1 C D 4 +0 . 0 20 . 0 40 . 0 10 . 0 30 . 0 20 . 1 40 . 0 30 . 0 50 . 0 10 . 0 20 . 0 80 . 0 60 . 0 40 . 1 30 . 0 90 . 0 20 . 0 50 . 0 20 . 0 00 . 1 0
*Positive CD8+ T cell assays are indicated in bold, italics.Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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Among the 8 IE-1 epitopes we identified, IE-1199–207 and
IE-1379–386 have been previously described as restricted to
HLA-B*18 [22]. We found 2 similar epitopes reactive with
donor 15 who also expressed HLA-B*18 (Table 8). Unfor-
tunately, donor 15 PBMCs could not be expanded in vitro
with either peptide, therefore we could not confirm these
restrictions.
CD4+ T cell responses to pp65 peptides
After testing pp65 peptide subpools against PBMCs from
all 20 seropositive subjects, 5 subpools stimulated CD4+
cells in each of the 10 subjects who were responsive to the
pp65 library (Table 9). Subpool 8 stimulated CD4+ cells
from 1 subject, subpool 6 from 3 subjects, subpool 10
from 4 subjects, and subpool 13 from 5 subjects (Table 9).
All 15-mers in each reactive subpool were tested against
PBMCs from the 10 subjects, revealing a total of 6 reactive
pp65 15-mer epitopes. The peptide pp65221–235 was iden-
tified as the reactive 15-mer in subpool 6, pp65285–299 in
subpool 8, and pp65365–379 in subpool 10 (Figure 6). Sub-
pool 13 yielded 3 reactive 15-mers; pp65489–503, pp65505–
519, and pp65509–523 (Figure 7).
Epitope pp65221–235 reacted with PBMCs from donors 8,
10, and 12 (Table 10). Donor 12 PBMCs were in vitro sen-
Identification of CMV pp65 15-mer and nanomer epitopes recognized by CD8+ T cells Figure 3
Identification of CMV pp65 15-mer and nanomer epitopes recognized by CD8+ T cells. PBMCs from CMV-serop-
ositive subjects reactive with peptides in a pp65 subpool were tested against all the individual 15-mers in each subpool. Follow-
ing the identification of reactive 15-mers, nanomers overlapping at 8 amino acids and spanning the reactive 15-mer peptides 
were tested against PBMCs from the reactive subject. The reactive 15-mer and nanomer peptides are shown. Testing of cells 
from 7 subjects led to the identification of 6 pp65 15-mers reactive with CD8+ T cells. Testing of the overlapping nanomers 
identified 5 epitopes. Cells from donor 3 were not available to test with the nanomer peptides. Although CD8+ T cells from 
donor 10 were reactive with peptides in subpool 6 and a reactive 15-mer, pp65221–235, was identified, no reactive nanomer was 
identified. NT = not tested.
pp65 Sub-pool 15-mer 9-mer
Sub-pool 3
0.27% IFN-γ+
Sub-pool 5
0.13% IFN-γ+
Sub-pool 6
0.21% IFN-γ+
Sub-pool 13
0.12% IFN-γ+
Sub-pool 11
0.17% IFN-γ+    
0.36% IFN-γ+
0.13% IFN-γ+
pp65117-131
0.62% IFN-γ+
pp65185-199
0.09% IFN-γ+
pp65221-235 
0.25% IFN-γ+
pp65489-509
1.05% IFN-γ+
pp65413-427
0.35% IFN-γ+   
0.47% IFN-γ+    
pp65417-431
0.25% IFN-γ+
pp65123-131
0.26% IFN-γ+
pp65188-196
0.06% IFN-γ+
None 
identified
pp65495-503  
0.27% IFN-γ+
pp65417-425
NT  
0.91% IFN-γ+
pp65418-426 
0.25% IFN-γ+
Donor 19
Donor 5
Donor 10
Donor 13
Donor 14
Donor 7
Donor 3Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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sitized with pp65221–235, and reacted with pp65221–235,-
loaded EBV-LCLs expressing DRB1*15 and DRB5*01. It is
likely that pp65221–235 is presented by DRB1*15 since 2 of
the 3 donors expressed DRB1*15 but only donor 12
expressed DRB5*01. In addition, pp65225–239 has previ-
ously been reported to be restricted to DRB1*15[23].
Pp65365–379 stimulated cells from 4 donors all expressing
HLA-DRB1*11 (Table 10). PBMCs from donor 11 were in
vitro sensitized with pp65365–379, and produced IFN-γ
when tested against pp65365–379  -loaded EBV-LCLs
expressing HLA-DRB1*11, but not when tested against
those expressing HLA-DRB1*0102, DRB3*0202,
DQB1*0301, and DQB1*0501. The testing of this pep-
tide against a second subject, donor 6, revealed similar
results. Two similar epitopes, pp65361–376 and pp65361–
375, have been described as restricted to HLA-
DR11[11,24].
Epitope pp65489–503 reacted with 3 donors, all of whom
expressed HLA-DRB3*02 (Table 10). Donor 6 PBMCs
that were in vitro sensitized with pp65489–503, produced
IFN-γ when tested against EBV-LCLs expressing HLA-
DRB3*02, but not when tested against the other donor 6
class II antigens. Although we found that pp65489–503 was
restricted to DRB3*02, others have described this peptide
as restricted to DRB1*11 and DRB1*03 [24].
Epitope pp65505–519  was reactive with PBMCs from
donors 6 and 17 and testing of donor 6 pp65505–519 ex
vivo sensitized PBMCs against pp65505–519-loaded EBV-
LCLs revealed presentation by DQB1*0502. Donor 17 did
not express DQB1*0502, but cells were not available for
additional testing. The epitope pp65505–523  has been
reported to be restricted to DRB1*01[23] and DR52[11].
Epitope pp65509–523 reacted with PBMCs from donors 12
and 14, and testing donor 12 in vitro sensitized PBMCs
against loaded EBV-LCLs revealed presentation by
DRB3*0101. Donor 14 did not express DRB3*0101 how-
ever, an adequate number of cells were not available for in
vitro sensitization and testing. The epitope pp65509–524
was previously reported to be restricted to DRB1*03[24].
Pp65285–299  reacted with cells from donor 7, who
expressed both HLA-DRB1*0401 and HLA-DRB1*0701
Table 7: Proportion of Peripheral Blood CD8+ T Cells From 20 Healthy CMV-Seropositive Subjects Producing Intracellular IFN-γ 
Following Stimulation With a Library of 120 CMV IE-1 15-mer Peptides and Each of 12 Subpools of 10 Peptides
CD8+ T Cells Producing Intracellular IFN-γ in Each Donor (%)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Library 0.05 0.46 2.06 0.04 1.65 0.87 1.37 0.13 0.15 0.33 0.32 0.06 0.02 0.12 1.41 0.05 0.05 0.02 0.03 0.08
Subpool
1 0.04 0.03 0.08 0.05 0.01 0.03 0.01 0.11 0.04 0.05 0.04 0.05 0.04 0.05 0.03 0.05 0.02 0.02 0.01 0.00
2 0.05 0.07 0.06 0.01 0.07 0.04 0.06 0.05 0.10 0.03 0.02 0.04 0.02 0.02 0.01 0.05 0.01 0.01 0.01 0.01
3 0.06 0.05 0.04 0.04 0.95 0.03 0.02 0.08 0.02 0.26 0.29 0.10 0.01 0.05 0.02 0.08 0.01 0.01 0.01 0.02
4 0.06 0.07 0.16 0.05 0.01 0.05 0.00 0.00 0.07 0.04 0.04 0.06 0.03 0.03 0.02 0.08 0.04 0.03 0.00 0.02
5 0.03 0.04 0.05 0.00 0.05 0.04 0.05 0.07 0.17 0.03 0.07 0.03 1.28 0.04 1.60 0.08 0.03 0.06 0.01 0.02
6 0.02 0.02 0.17 0.03 0.05 0.10 0.01 0.06 0.06 0.06 0.06 0.06 0.03 0.12 0.05 0.11 0.02 0.01 0.04 0.00
7 0.04 0.01 0.02 0.03 0.01 0.03 0.03 0.09 0.01 0.04 0.05 0.07 0.06 0.03 0.07 0.05 0.01 0.02 0.02 0.00
8 0.06 0.43 1.65 0.00 0.33 1.05 1.39 0.07 0.02 0.01 0.05 0.04 0.03 0.12 0.06 0.00 0.03 0.01 0.06 0.00
9 0.04 0.02 0.03 0.08 0.02 0.05 0.02 0.14 0.03 0.04 0.09 0.08 0.03 0.04 0.11 0.02 0.02 0.04 0.04 0.00
10 0.04 0.07 0.08 0.03 0.03 0.05 0.00 0.07 0.08 0.05 0.05 0.07 0.04 0.05 0.25 0.05 0.01 0.04 0.04 0.00
11 0.01 0.01 0.09 0.03 0.05 0.06 0.05 0.09 0.04 0.02 0.08 0.07 0.02 0.01 0.05 0.07 0.03 0.01 0.01 0.02
12 0.02 0.05 0.11 0.06 0.07 0.03 0.02 0.06 0.03 0.03 0.05 0.08 0.06 0.04 0.04 0.10 0.02 0.04 0.03 0.02
Positive assays are indicated in bold and italics.
Table 6: Individual pp65 Epitopes that Induced Intracellular IFN-γ Production by CD8+ T Cells, the HLA Type of Donors With 
Reactive CD8+ T Cells, and HLA Antigen Restrictions of Each Epitope
Epitope(s) Donor HLA-A* HLA-B* HLA-C* HLA Antigen Restriction Published Antigen Restriction
pp65123–131 19 03, 29 35, 44 04, 1601 B*35 pp65123–131 B*3501 [20]
pp65188–196 05 11, 68 44, 45 05, 06 No cells available pp65186–196 A*6801/2 [21]
pp65417–425 and pp65418–426 03 01, 31 07, 27 0202, 0702 No cells available
07 01, 0201 07, 35 04, 07 No cells available pp65417–426 B*0702 [8,19]
14 010101, 2601 070201, 3801 070201, 120301 HLA-B*07
pp65 495–503 13 0201, 0201 15, 18 03, 07 Not tested pp65495–503 A*0201 [13,30]
The HLA antigen restrictions identified are shown in bold.Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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(Table 10). Although additional PBMCs were not availa-
ble for testing, a similar epitope, pp65281–295, was previ-
ously found to be restricted to both HLA-DR*4 and HLA-
DR*7[11].
CD4+ T cell responses to IE-1
Testing with both the IE-1 library and the 12 subpools did
not reveal active CD4+ populations from any subjects
(Table 11).
Discussion
The aim of this investigation was to map CMV pp65 and
IE-1 epitopes in 20 CMV-seropositive healthy subjects in
order to identify peptides that may be important in vacci-
nation, adoptive immunotherapy, and the monitoring of
transplant recipients. Among the 20 subjects, CD8+ T cell
responses to pp65 and IE-1 were detected in a similar pro-
portion of patients: 35% versus 40%. However, CD4+ T
cell responses to pp65 were more common than
responses to IE-1, as 50% of subjects reacted to pp65 but
none reacted to IE-1. Using similar methodology, Kern et
al also found CD8+ T cell responses in healthy subjects to
both pp65 and IE-1[9,11]. While they did not specifically
screen for IE-1 epitopes that were presented by CD4+ T
cells, a comparison of CD4+ T cell responses to pp65 pep-
tides with responses to CMV lysate suggested that pp65
was a dominant target of the CMV-specific CD4+ T cell
response[11]. A recent analysis of overlapping 15-mers
spanning 213 CMV open reading frames including pp65
and IE-1, by Sylwester et al found that the CD8+ and
CD4+ T cell responses were directed to peptides in a vari-
ety of proteins,[25]. In addition, they found that CD8+ T
cell responses to both pp65 and IE-1 were strong and the
CD4+ T cell responses were strong to pp65 but weak to IE-
1 which supports the results of our study [25].
We identified 4 pp65 and 8 IE-1 nanomers presented by
HLA class I, and 6 pp65 15-mers presented by HLA class
II. While all 4 of the pp65 CMV class I epitopes have been
previously described, 6 of the 8 IE-1 class I epitopes, and
2 of the 6 pp65 class II epitopes have not. The pp65
epitopes and restrictions that we identified were similar or
identical to those reported previously, but the IE-1 class I
epitopes had either not been described or we identified
HLA restrictions that differed from those reported.
Four of the 6 new IE-1 class I epitopes we identified were
restricted to HLA-C antigens, a finding that may be corre-
Identification of CMV IE-1 15-mer and nanomer epitopes from 3 peptide subpools reactive with CD8+ T cells Figure 4
Identification of CMV IE-1 15-mer and nanomer epitopes from 3 peptide subpools reactive with CD8+ T cells. 
PBMCs from 4 donors were reactive with peptides in IE-1 subpools 3, 5, and 10. Testing of all 15-mers in each subpool identi-
fied 3 nanomers reactive with CD8+ T cells, one from each subpool. Testing of the 6 overlapping nanomers spanning each 
reactive 15-mer lead to the identification of 3 nanomer epitopes.
IE-1 Sub-pool 15-mer 9-mer
Sub-pool 5
1.60% IFN-γ+
Sub-pool 10
0.25% IFN-γ+
IE-1197-211
1.66% IFN-γ+
IE-1373-387
0.36% IFN-γ+
IE-1198-206 
4.58% IFN-γ+
IE-1378-386
0.87% IFN-γ+
Donor 15
Donor 5
Donor 10
Donor 11
Sub-pool 3
0.95% IFN-γ+
0.26% IFN-γ+
0.29% IFN-γ+
IE-181-95
0.53% IFN-γ+
0.18% IFN-γ+
0.16% IFN-γ+
IE-187-95
1.25% IFN-γ+
0.20% IFN-γ+
0.19% IFN-γ+Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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Identification of CMV pp65 15-mer and nanomer epitopes from peptide subpool 8 that were reactive with CD8+ T cells Figure 5
Identification of CMV pp65 15-mer and nanomer epitopes from peptide subpool 8 that were reactive with 
CD8+ T cells. Testing of IE-1 15-mers from subpool 8 against cells from donor 2 (gold bar), donor 5 (red bar), donor 6 (light 
blue bar), and donor 7 (navy blue bar) revealed that the peptide IE-1297–311 was reactive with donor 6, IE-1305–319 was reactive 
with donor 7, IE-1309–323 was reactive with donors 2 and 6, and IE-1313–327 was reactive with donor 5 (Panel A). Testing of the 6 
nanomers overlapping IE-1297–311 against cells from donor 6 revealed that IE-1300–308 was the dominant nanomer (Panel B). Test-
ing of the nanomers spanning the overlapping 15-mers IE-1305–319, IE-1309–323, and IE-1313–327 against PBMCs from donors 2, 5, 
and 7 identified 4 nanomers that were reactive with CD8+ T cells: IE-1305–313, IE-1308–316, IE-1312–320 and IE-1319–327, (Panel C).
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lated to the fact that all of our subjects and EBV-LCLs were
HLA typed at high-resolution. Because HLA-C antigen typ-
ing results were ambiguous prior to the advent of molec-
ular genotyping, the availability of precise molecular
typing for this study may have permitted the identifica-
tion of epitopes not possible in the past when molecular
methods were not available or were less precise.
While the conventional thought has been that unique
peptides are each presented by a specific HLA allele, some
CMV epitopes are presented by multiple alleles. Epitopes
for HLA class I antigens are generally believed to be very
restrictive, with epitopes binding to specific HLA-types.
Our results suggest that this is not entirely true for IE-1
class I epitopes as the HLA restrictions were somewhat
promiscuous. We found that the epitope IE-1319–327 was
restricted to HLA-A*68, while a similar epitope IE-1316–324
has been described as restricted to A*0201. We also found
that IE-1308–316 was restricted to HLA-C*07, but IE-1309–
317 is reported to be restricted to HLA-B*0702 [19]. In pre-
vious studies, we found that the epitopes pp65341–349 and
pp65341–350 are presented by HLA-A*0101, HLA-A*2402,
and HLA-Cw*0402 [14,26].
We found that 1 region of IE-1, amino acid residues 300
to 327, to be more immunogenic than other regions. We
identified 5 epitopes in this region, in addition to the 3
other epitopes previously identified[9,19,27]. This region
was particularly immunogenic for HLA-C*07 as we iden-
tified 3 HLA-C*07 restricted epitopes in this region.
Table 9: Proportion of Peripheral Blood CD4+ T Cells From 20 Healthy CMV-Seropositive Subjects Producing Intracellular IFN-γ 
Following Stimulation With a Library of 138 CMV pp65 15-mer Peptides and Each of 14 subpools of 10 Peptides*
CD4+ T Cells Producing Intracellular IFN-γ in Each Donor (%)
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0
Library 0.16 0.06 0.00 0.06 0.11 0.76 0.11 0.65 0.08 0.21 3.33 0.18 0.20 1.34 0.23 0.02 0.15 0.03 0.04 0.01
Subpool
1 0.01 0.01 0.02 0.01 0.02 0.03 0.00 0.03 0.02 0.01 0.03 0.05 0.08 0.05 0.04 0.00 0.02 0.01 0.01 0.04
2 0.05 0.09 0.01 0.03 0.05 0.05 0.02 0.04 0.02 0.01 0.03 0.06 0.02 0.06 0.03 0.02 0.03 0.04 0.01 0.03
3 0.03 0.02 0.01 0.01 0.03 0.03 0.04 0.05 0.05 0.03 0.03 0.06 0.03 0.06 0.06 0.00 0.03 0.02 0.04 0.02
4 0.01 0.06 0.02 0.01 0.03 0.06 0.00 0.09 0.01 0.02 0.04 0.04 0.01 0.03 0.04 0.01 0.01 0.02 0.02 0.00
5 0.02 0.04 0.01 0.01 0.02 0.02 0.00 0.04 0.04 0.01 0.04 0.05 0.02 0.07 0.02 0.02 0.01 0.00 0.01 0.01
6 0.02 0.04 0.01 0.04 0.01 0.03 0.01 0.45 0.04 0.11 0.02 0.18 0.02 0.01 0.02 0.02 0.01 0.04 0.01 0.03
7 0.01 0.05 0.04 0.01 0.01 0.02 0.02 0.03 0.01 0.07 0.02 0.06 0.05 0.04 0.07 0.02 0.02 0.07 0.02 0.01
8 0.04 0.04 0.01 0.03 0.02 0.09 0.05 0.12 0.01 0.01 0.04 0.08 0.00 0.07 0.05 0.02 0.01 0.03 0.01 0.03
9 0.06 0.13 0.03 0.03 0.03 0.05 0.05 0.04 0.03 0.01 0.05 0.05 0.01 0.06 0.02 0.02 0.01 0.03 0.02 0.09
10 0.14 0.02 0.00 0.03 0.05 0.56 0.00 0.10 0.05 0.04 2.76 0.08 0.01 0.96 0.03 0.02 0.02 0.01 0.02 0.00
11 0.03 0.02 0.00 0.00 0.02 0.15 0.00 0.08 0.01 0.01 0.06 0.13 0.01 0.07 0.01 0.01 0.01 0.01 0.00 0.01
12 0.04 0.03 0.01 0.00 0.02 0.04 0.01 0.05 0.04 0.01 0.01 0.04 0.00 0.06 0.03 0.02 0.02 0.01 0.01 0.05
13 0.02 0.03 0.02 0.03 0.03 0.27 0.00 0.13 0.07 0.07 0.05 0.12 0.14 0.42 0.13 0.01 0.12 0.02 0.01 0.00
14 0.03 0.06 0.02 0.01 0.02 0.09 0.00 0.11 0.07 0.01 0.03 0.08 0.01 0.09 0.02 0.01 0.01 0.01 0.02 0.00
* Subpool 14 contained 8 peptides
Positive assays are indicated in bold and italics.
Table 8: Individual IE-1 Epitopes that Induced Intracellular IFN-γ Production by CD8+ T Cells, the HLA Type of Donors With Reactive 
CD8+ T Cells, and The HLA Antigen Restriction of Each Epitope.
Epitope Donor HLA-A* HLA-B* HLA-C* HLA Antigen Restriction Published Antigen Restriction
IE-187–95 05 11, 68 44, 45 05, 06
10 0301, 68 53, 58 04, 06
11 26, 74 15, 5802 0602, 1601 C*0602
IE-1198–206 15 0201, 30 18, 44 0501 † IE-1199–207 B*18 [22]
IE-1300–308 06 26, 30 35, 57 04, 18 No cells available IE-1297–304 A*0201 [27]
IE-1305–313 07 01, 0201 07, 35 04, 07 C*0702
IE-1308–316 02 24, 32 07, 40 02, 07 C*07 IE-1309–317 B*0702 [9]
07 01, 0201 07, 35 04, 07
IE-1312–320 07 01, 0201 07, 35 04, 07 C*07
IE-1319–327 05 11, 68 44, 45 05, 06 A*68 IE-1316–324 A*0201 [19]
IE-1378–386 15 0201, 30 18, 44 0501, 0501 † IE-1379–387 B*18 [22]
† Cells from donor 15 did not expand when stimulated with IE-1198–206 and IE-1378–386.
The HLA antigen restrictions identified are shown in bold.Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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Although pp65495–503 has been found to presented by
HLA-A*02[8,13], the 15-mer in our pp65 library that
encompassed this epitope, pp65489–503, stimulated CD8+
T cells from only 1 of 6 HLA-A*02 CMV seropositive sub-
jects tested. To determine if the lack of response to
pp65489–503 was because the cells were not responsive to
pp65495–503 or because the epitope was not presented in
the context of the 15-mer, we tested the 9-mer, pp65495–
503, against PBMCs for all 5 HLA-A*02 subjects who had
not responded to pp65489–503. Similarly, CD8+ cells from
none of these subjects produced significant quantities of
intracellular IFN-γ in response to pp65495–503 stimulation.
Our study differed from most other studies in that we
screened the peptide libraries against cells that had not
been sensitized in vitro, while the studies that first identi-
fied pp65495–503  as an immune dominant HLA-A*02
restricted epitope used T cells that had been stimulated
with CMV-infected fibroblasts[8,13]. These results suggest
that the baseline frequency of CTLs in HLA-A*0201
healthy subjects that are restricted to pp65495–503 is usually
low, but expand robustly when challenged with CMV
antigens.
To provide optimum protection from CMV infection and
disease, vaccines that elicit both CD8+ and CD4+
responses are required[5,23]. Cytotoxic T cells (CTL) pre-
vent CMV infection from developing into CMV disease,
and CD4+ T cell responses maintain CTLs[5]. Several vac-
cines to CMV have been tested and found to have some
efficacy, including live attenuated vaccines, subunit vac-
cines, and peptide vaccines[28]. Subunit vaccines have
focused on gB glycoprotein because it is the primary target
of natural antibodies, and pp65 because it is the major tar-
get of CTLs. Additionally, pox virus-vectored vaccines
Identification of CMV pp65 15-mer epitopes from 3 peptide subpools that were reactive with CD4+ T cells Figure 6
Identification of CMV pp65 15-mer epitopes from 3 peptide subpools that were reactive with CD4+ T cells. 
PBMCs from 8 donors were reactive with peptides in subpools 6, 8, and 10. Testing of all 15-mers in each subpool identified 
three15-mers that were reactive with CD4+ T cells, one from each subpool.
Sub-pool 6
Donor 8
Donor 10
Donor 12
1.05% IFN-γ+
0.17% IFN-γ+
0.07% IFN-γ+
0.45% IFN-γ+
0.11% IFN-γ+
0.18% IFN-γ+
pp65221-235
pp65 Sub-pool 15-mer
Sub-pool 8 pp65285-299
Donor 7 0.05% IFN-γ+ 0.10% IFN-γ+
Donor 1
Donor 6
Donor 14
Donor 11
Sub-pool 10 pp65365-379
0.14% IFN-γ+
0.96% IFN-γ+
2.76% IFN-γ+
0.56% IFN-γ+
0.22% IFN-γ+
0.45% IFN-γ+
1.23% IFN-γ+
0.56% IFN-γ+Journal of Translational Medicine 2007, 5:17 http://www.translational-medicine.com/content/5/1/17
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expressing pp65 have stimulated CD8+ T cell responses in
CMV-seronegative subjects. Our finding of naturally
occurring CD8+ and CD4+ T cell responses to pp65 in
healthy subjects also supports its use in subunit vaccines.
The naturally occurring CD8+ T cell responses to IE-1 that
we found in a large proportion of healthy subjects sup-
ports IE-1 addition to vaccines. In fact, a trivalent DNA
vaccine containing gB, pp65, and IE-1 is being tested in
phase I clinical trials[28].
In one study of lung and heart transplant recipients have
revealed that protection from CMV disease is more closely
associated with the CD8+ T cell responses to IE-1 than to
pp65, indicating that IE-1 is a good candidate for CMV
Table 10: Individual pp65 Epitopes that Induced intracellular IFN-γ Production by CD4+ T Cells, the HLA Type of Donors With 
Reactive CD4+ T Cells, and the HLA Antigen Restriction of Each Epitope
Peptide(s) Donor DRB1* DRB- DQB1* HLA Antigen Restriction Published Antigen Restriction
12 03021, 1503 3*01, 5*01 06 DRB1*15 or DRB5*01 pp65225–239 DR15 [23]
pp65221–235 08 13031, 1503 3*02, 3*02 02, 06
10 0701, 1302 3*0301, 4*0401 0202, 0604 No cells available
pp65285–299 07 0401, 0701 4*01, 4*01 0303, 03 No cells available pp65281–295 DR4, 7 [11]
pp65365–379 01 0901, 11 3*00, 4*01 02, 06 pp65361–376 DR11 [24]
06 11, 16 3*02, 5*02 0301, 05
11 0102, 1101 3*0202 0301, 0501 DRB1*11 pp65361–375 DR11 [11]
14 0402, 1101 3*02, 4*0103 0301, 0302
pp65489–503 06 11, 16 3*02, 5*02 0301, 05 DRB3*02
13 13, 1501 3*02, 5*01 06 pp65489–503
14 0402, 1101 3*02, 4*0103 0301, 0302 DR11,3 [24]
17 13,1503 3*02, 5*01 06 pp65505–523 DR52 [11]
pp65505–519 06 11, 16 3*02, 5*02 0301, 05 DQB1*0502 pp65505–523 DR1 [23]
pp65509–523 12 03021, 1503 3*01, 5*01 06 DRB3*0101
14 0402, 1101 3*02, 4*0103 0301, 0302 No cells available pp65509–524 DR3 [24]
The HLA antigen restrictions identified are shown in bold
Identification of CMV pp65 15-mer epitopes from peptide subpool 13 that were reactive with CD4+ T cells Figure 7
Identification of CMV pp65 15-mer epitopes from peptide subpool 13 that were reactive with CD4+ T cells. 
PBMCs from 5 donors were reactive with pp65 peptides in subpool 13. Testing of all 15-mers in subpool 13 identified three 
15-mers that were reactive with CD4+ T cells, pp65489–503, pp65505–519, and pp65509–523.
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vaccines[29]. However, the lack of naturally occurring
CD4+ T cell responses to IE-1 suggests that it may not be
as useful as pp65 in a monovalent vaccine since both
CD8+ and CD4+ responses to pp65 are frequently found
in healthy CMV-seropositive positive subjects.
The characterization of pp65 and IE-1 epitopes will be val-
uable for monitoring patients treated with vaccines or
adoptive immunotherapies, and these epitopes alone or
in conjunction with HLA class I tetramers or pentamers
can be used to follow the immune responses to these ther-
apies. In addition, peptides, and HLA tetramers and pen-
tamers can be used to assess the host immune response to
CMV.
In conclusion, by screening healthy, CMV-seropositive
subjects with pp65 and IE-1 peptides, we identified sev-
eral new IE-1 epitopes and confirmed several other IE-1
and pp65 epitopes. Similar numbers of CMV pp65 and IE-
1 HLA class I epitopes were detected, and one region of IE-
1 was rich in HLA class I epitopes, especially those
restricted to HLA-C*07. Although pp65 was rich in HLA
class II epitopes, no IE-1 class II epitopes were identified.
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